ZCP
DYN icon

Z3 Capital Partners’s Dyne Therapeutics DYN Stock Holding History

Z3 Capital Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Sell
18,925
-200
-1% -$3.72K 0.09% 128
2026
Q1 		$347K Buy
19,125
+4,075
+27% +$70.3K 0.09% 135
2025
Q4 		$294K Buy
+15,050
New +$285K 0.07% 148

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Z3 Capital Partners's DYN Position: Q2 2026 in Review

Z3 Capital Partners reduced its Dyne Therapeutics (DYN) stake by 1% in Q2 2026, selling an estimated $3.72K and leaving 18,925 shares worth $420K. The position accounts for 0.09% of the portfolio, ranked #128.

Z3 Capital Partners first reported a position in DYN in Q4 2025 and has held it in 3 quarters since. 230 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Z3 Capital Partners held 18,925 shares of Dyne Therapeutics worth $420K as of Q2 2026.
  • Z3 Capital Partners sold 200 Dyne Therapeutics shares in Q2 2026, an estimated $3.72K.
  • Dyne Therapeutics made up 0.09% of Z3 Capital Partners's portfolio in Q2 2026, its #128 holding.
  • Z3 Capital Partners first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 230 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Z3 Capital Partners's 13F filing for Q2 2026, filed 28 Jul 2026.